Multiple therapeutic strategies have been explored to disrupt CD47 signalling in GBM, including monoclonal antibodies, soluble SIRPα fusion proteins, recombinant or peptide fragments derived from TSP‐1, dual CD47/CD36 inhibitors, and antisense oligonucleotides. This evidence concerns the gene SIRPA and glioblastoma.